ClinicalTrials.gg
Active, not recruitingNCT06508658EPCORE DLBCL-4Updated Apr 8, 2026

A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

A Phase 3 interventional study of Epcoritamab and Rituximab in Diffuse Large B-Cell Lymphoma, sponsored by Genmab. Active, not recruiting at 176 sites in 28 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-08.

Sponsored by Genmab · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
379
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies testing epcoritamab in Lymphoma, Large B-Cell, Diffuse — 16 open to participants now, 23 under way, 3 of them phase 3. epcoritamab · Lymphoma, Large B-Cell, Diffuse.

Enrollment
3rd of 24
379 · median 41
Started
2024
with 2 others
Phase 3
3 of 24
none open now
Primary completion
2028-03
later than 10 of 22 live
Registered
10th of 24
by date
Lead sponsor
8 of 24
Genmab

Among the 24 studies testing epcoritamab in Lymphoma, Large B-Cell, Diffuse, this one is the 3rd largest by enrollment, is one of 3 that started in 2024, is one of 3 in phase 3, reaches primary completion later than 10 of the 22 other live ones, and was the 10th registered.

Lymphoma, Large B-Cell, Diffuse

1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Open to participants now

16 of the 24 studies testing epcoritamab in Lymphoma, Large B-Cell, Diffuse are open now, in 5 countries. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 16 open studies →

About epcoritamab

epcoritamab: first FDA approval 2023 (EPKINLY), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 266 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 177 (67%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies testing epcoritamab in Lymphoma, Large B-Cell, Diffuse, or all of them as a file.
02

Study summary

B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). This study will assess how safe and effective epcoritamab plus lenalidomide (E-Len) is compared to rituximab plus gemcitabine and oxaliplatin (R-GemOx) )in treating adult participants with relapsed or refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL). Adverse events and change in disease condition will be assessed.

Epcoritamab is an investigational drug being developed for the treatment of DLBCL. Study doctors put the participants in 1 of 3 groups, called treatment arms. Each group receives a different treatment. Around 360 adult participants with R/R DLBCL will be enrolled in approximately 165 sites across the world.

Participants in arm A will receive subcutaneous (SC) injections of epcoritamab plus oral lenalidomide capsules (E-Len) for up to 12 cycles (each cycle is 28 days). Participants in arm B will receive intravenously (IV) infused R-GemOx for up to 4 cycles (each cycle is 28 days). Participants in arm C will receive SC injections of epcoritamab for up to 12 cycles (each cycle is 28 days).

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

03

Conditions studied

  • Diffuse Large B-Cell Lymphoma

Keywords

  • Epcoritamab
  • Lenalidomide
  • Rituximab
  • Gemcitabine
  • Oxaliplatin
  • Diffuse Large B-Cell Lymphoma
  • DLBCL
  • Epkinly
  • ABBV-GMAB-3013
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Performance status score of 0 to 2.
  • confirmed CD20+ Diffuse Large B-Cell Lymphoma (DLBCL) and documented in the most recent and representative pathology report, inclusive of the following according to the World Health Organization (WHO) 2022 as per the protocol.
  • Must have (R/R) disease and have been previously treated with at least 1 line of systemic antineoplastic therapy including anti-CD20 mAb-containing combination chemotherapy since DLBCL diagnosis.
  • Participant must meet at least 1 of the following criteria:

    • Failed prior stem cell transplant (ASCT), defined as relapsed after ASCT or been refractory to high-dose therapy (HDT)-ASCT.
    • Not be considered a candidate for ASCT due to age, performance status, comorbidities and/or insufficient response to prior treatment, or have refused ASCT.
    • Be ineligible for or unable to receive chimeric antigen receptor T-cell (CAR-T) meeting at least 1 of the following criteria:

      • Unable to receive CAR-T therapy due to fitness and/or comorbidity.
      • Lymphocyte apheresis failure.
      • Unwilling to receive CAR-T therapy.
      • Unable to receive CAR-T therapy due to financial, geographic, insurance, access, and/or manufacturing constraints.
      • Relapsed/progressed after having achieved at least a Partial Response (PR) or Complete Response (CR) while on prior CAR-T therapy.
  • Must have .
  • > 3 months on standard of care treatment at the time of enrolling in the study

Exclusion criteria

Exclusion Criteria:

  • Current evidence of primary central nervous system (CNS) lymphoma or known CNS involvement by lymphoma including , at screening.
  • History of prior treatment with a bispecific antibody targeting CD3 and CD20 or prior treatment with rituximab plus gemcitabine and oxaliplatin (R-GemOx) or gemcitabine and oxaliplatin (GemOx).
  • Documented refractoriness to lenalidomide.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
379 participants (actual)

Study arms

  • Experimental
    Arm A: Epcoritamab Plus Lenalidomide (E-Len)

    Participants will receive E-Len for up to 12 cycles (each cycle is 28 days).

    Drug: Epcoritamab · Drug: Lenalidomide

  • Experimental
    Arm B: Rituximab Plus Gemcitabine and Oxaliplatin (R-GemOx)

    Participants will receive R-GemOx for up to 4 cycles (each cycle is 28 days)

    Drug: Rituximab · Drug: Oxaliplatin · Drug: Gemcitabine

  • Experimental
    Arm C: Epcoritamab

    Participants will receive epcoritamab for up to 12 cycles (each cycle is 28 days).

    Drug: Epcoritamab

Interventions

06

What researchers measure

Primary outcomes

  1. Arm A vs Arm B: Progression-Free Survival (PFS)

    PFS is defined as the duration from the date of randomization to the date of disease progression determined per Lugano 2014 criteria as assessed by an independent review committee (IRC), or death, whichever occurs first.

    Time frame: Up to 4 Years

Secondary outcomes

  1. Arm A vs Arm B: Percentage of Participants Who Achieve Complete response (CR)

    CR is defined as the percentage of participants who achieve CR determined by Lugano 2014 criteria, as assessed by an IRC that is blinded to treatment arm prior to the initiation of new anti-lymphoma therapy.

    Time frame: Up to 4 Years

  2. Arm A vs Arm B: Overall Survival (OS)

    OS is defined as the time from randomization to death from any cause.

    Time frame: Up to 4 Years

  3. Arm A vs Arm B: Percentage of Participants Who Achieve Minimal Residual Disease (MRD) Negativity Rate

    The MRD negativity rate is defined as the percentage of participants who achieve MRD negative status prior to the initiation of new anti-lymphoma therapy.

    Time frame: Up to 4 Years

07

Study locations

176 sites

Showing the first 100 of 176 sites across 28 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Genmab is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

Supporting information: Study protocol, Statistical analysis plan

Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/

Access criteria: To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Mar 2028, 43 months after the start.

Of 37 industry-sponsored phase 3 interventional studies under Lymphoma, Large B-Cell, Diffuse, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 82. This study's planned 43 months is below that.

Counting every sponsor, half of 73 studies reached it within 57 months; a quarter within 39 and three quarters within 99.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 11, 2024
First posted
Jul 18, 2024
StartActual
Aug 13, 2024
Primary completionEst.
Mar 2028
CompletionEst.
Mar 2028
Last update
Apr 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06508658
Lead sponsor
Genmab
Collaborators
AbbVie
Responsible party
Sponsor
First posted
Jul 18, 2024
Start date
Aug 13, 2024
Primary completion
Mar 2028 (estimated)
Completion
Mar 2028 (estimated)
Last update
Apr 8, 2026

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Epcoritamab · Rituximab · Lenalidomide · Oxaliplatin · Gemcitabine

Start the discussion